$IVVD
Invivyd, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004586 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.66M $11.05M $842.0K
YoY Change 356.82% 1212.59%
% of Gross Profit
Research & Development $68.43M $45.37M $7.251M
YoY Change 359.23% 525.65%
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change
% of Gross Profit
Operating Expenses $83.09M $60.42M $48.01M
YoY Change 27.19% 25.85%
Operating Profit -$60.42M -$48.01M
YoY Change 25.85%
Interest Expense $1.620M $48.00K $0.00
YoY Change 20150.0%
% of Operating Profit
Other Income/Expense, Net -$1.572M $43.00K $0.00
YoY Change
Pretax Income -$83.04M -$60.38M -$48.01M
YoY Change 27.13% 25.76%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$83.04M -$60.38M -$48.01M
YoY Change 27.13% 25.76%
Net Earnings / Revenue
Basic Earnings Per Share -$0.98
Diluted Earnings Per Share -$758.8K -$985.0K -$442.4K
COMMON SHARES
Basic Shares Outstanding 111.3M 111.3M
Diluted Shares Outstanding 61.30M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $591.4M $666.3M
YoY Change 414.33%
Cash & Equivalents $542.2M $478.3M $48.58M
Short-Term Investments $49.19M $188.1M
Other Short-Term Assets $1.521M $579.0K
YoY Change 1421.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $616.7M $680.2M
YoY Change 425.39%
LONG-TERM ASSETS
Property, Plant & Equipment $83.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.297M $6.115M
YoY Change
Total Long-Term Assets $3.380M $6.115M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $616.7M $680.2M
Total Long-Term Assets $3.380M $6.115M
Total Assets $620.1M $686.3M
YoY Change 428.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.783M $17.56M
YoY Change -29.07%
Accrued Expenses $56.28M $35.49M
YoY Change 1044.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.06M $53.05M
YoY Change 374.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.000K $8.000K
YoY Change
Total Long-Term Liabilities $6.000K $8.000K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $62.06M $53.05M
Total Long-Term Liabilities $6.000K $8.000K
Total Liabilities $62.07M $53.06M
YoY Change 374.45%
SHAREHOLDERS EQUITY
Retained Earnings -$292.1M -$209.1M
YoY Change 347.2%
Common Stock $850.1M $842.3M
YoY Change 548374.84%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00
YoY Change -100.0%
Treasury Stock Shares $468.8K $0.00
Shareholders Equity $558.0M $633.2M -$48.18M
YoY Change
Total Liabilities & Shareholders Equity $620.1M $686.3M
YoY Change 428.27%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$83.04M -$60.38M -$48.01M
YoY Change 27.13% 25.76%
Depreciation, Depletion And Amortization $1.000K
YoY Change
Cash From Operating Activities -$73.21M -$54.21M -$1.143M
YoY Change 445.22% 4643.04%
INVESTING ACTIVITIES
Capital Expenditures -$84.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $138.0M -$188.6M $0.00
YoY Change
Cash From Investing Activities $137.9M -$188.6M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -749.0K 328.6M 49.72M
YoY Change -100.94% 560.9%
NET CHANGE
Cash From Operating Activities -73.21M -54.21M -1.143M
Cash From Investing Activities 137.9M -188.6M 0.000
Cash From Financing Activities -749.0K 328.6M 49.72M
Net Change In Cash 63.95M 85.76M 48.58M
YoY Change -3.7% 76.54%
FREE CASH FLOW
Cash From Operating Activities -$73.21M -$54.21M -$1.143M
Capital Expenditures -$84.00K
Free Cash Flow -$73.13M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001832038
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40703
dei Entity Registrant Name
EntityRegistrantName
Adagio Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1403134
dei Entity Address Address Line1
EntityAddressAddressLine1
1601 Trapelo Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 178
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
819-0080
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ADGI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
663432000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49720000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
363281000
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
111251660
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114988000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
478269000
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
188053000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13833000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2394000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
680155000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
117382000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6115000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2021Q3 us-gaap Assets
Assets
686270000
CY2020Q4 us-gaap Assets
Assets
117382000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
17564000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8153000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35485000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4919000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
53049000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13072000
CY2021Q3 adgi Early Exercise Liability
EarlyExerciseLiability
8000
CY2020Q4 adgi Early Exercise Liability
EarlyExerciseLiability
11000
CY2021Q3 us-gaap Liabilities
Liabilities
53057000
CY2020Q4 us-gaap Liabilities
Liabilities
13083000
CY2021Q3 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0
CY2020Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
169548000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111251660
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111251660
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28193240
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5593240
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
22600000
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
85000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-48008000
us-gaap Operating Income Loss
OperatingIncomeLoss
-143818000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48106000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
48000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
us-gaap Investment Income Interest
InvestmentIncomeInterest
80000
us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2021Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-5000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
842272000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
154000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209067000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65319000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
633213000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-65249000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
686270000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117382000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45366000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7251000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
114465000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7299000
CY2021Q3 adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
4000000
CY2020Q3 adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
39915000
adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
7500000
adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
39915000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11052000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
842000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21853000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
892000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
60418000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
48008000
us-gaap Operating Expenses
OperatingExpenses
143818000
us-gaap Operating Expenses
OperatingExpenses
48106000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60418000
CY2020Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-10000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
43000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
70000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60375000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-48008000
us-gaap Net Income Loss
NetIncomeLoss
-143748000
us-gaap Net Income Loss
NetIncomeLoss
-48106000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-38700000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-103362000
CY2021Q2 adgi Net Issuance Cost Of Convertible Preferred Stock
NetIssuanceCostOfConvertiblePreferredStock
337000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
66000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3342000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44673000
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60372000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48008000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-143745000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48106000
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.98
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-25.98
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-7.06
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-7.55
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61297086
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1847826
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20346771
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6375000
CY2021Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
1826000
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2261000
CY2020Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
291000
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
291000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-98000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-98000
CY2020Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
85000
CY2020Q3 adgi Net Issuance Cost Of Convertible Preferred Stock
NetIssuanceCostOfConvertiblePreferredStock
194000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-48008000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-48184000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-65249000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
587000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-144624000
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
504709000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5979000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-60375000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
633213000
us-gaap Profit Loss
ProfitLoss
-143748000
us-gaap Profit Loss
ProfitLoss
-48106000
us-gaap Share Based Compensation
ShareBasedCompensation
9908000
us-gaap Share Based Compensation
ShareBasedCompensation
7000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
39915000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
577000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
adgi Non Cash Payments
NonCashPayments
66000
adgi Non Cash Payments
NonCashPayments
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11342000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
47000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8909000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5210000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
30122000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1881000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-6016000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-3000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111524000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1143000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
188627000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-188627000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
335163000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
49706000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
330905000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000
adgi Payments Of Initial Public Offering Costs
PaymentsOfInitialPublicOfferingCosts
2636000
adgi Payments Of Initial Public Offering Costs
PaymentsOfInitialPublicOfferingCosts
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
48577000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114988000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
478269000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48577000
adgi Deferred Offering And Issuance Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingAndIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
749000
adgi Deferred Offering And Issuance Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingAndIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
0
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
40000000
CY2021Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
five-for-one
us-gaap Net Income Loss
NetIncomeLoss
-143700000
us-gaap Net Income Loss
NetIncomeLoss
-65300000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209100000
us-gaap Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments
RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
0
us-gaap Gain Loss On Investments Excluding Other Than Temporary Impairments
GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs and the valuation of common stock and resulting stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is monitoring the potential impact of the COVID-19 pandemic on its business and consolidated financial statements. The Company is not aware of any specific event or circumstance that would require any update to its estimates or judgments reflected in these consolidated financial statements or a revision of the carrying value of its assets or liabilities as of the issuance date of these condensed consolidated financial statements. These estimates may change as new events occur and additional information is obtained.</span>
CY2021Q3 adgi Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
0
CY2021Q3 adgi Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2020Q3 adgi Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
us-gaap Adjustment For Amortization
AdjustmentForAmortization
188050000
us-gaap Unrealized Gain On Securities
UnrealizedGainOnSecurities
3000
us-gaap Unrealized Loss On Securities
UnrealizedLossOnSecurities
0
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
188053000
CY2021Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2021Q3 adgi Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
7489000
CY2020Q4 adgi Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
2253000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
4558000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
41000
CY2021Q3 adgi Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
525000
CY2020Q4 adgi Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
78000
CY2021Q3 us-gaap Interest Receivable
InterestReceivable
682000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
579000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
22000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13833000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2394000
CY2021Q3 adgi Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
30011000
CY2020Q4 adgi Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
3853000
CY2021Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
2239000
CY2020Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
237000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2575000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
794000
CY2021Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
660000
CY2020Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
35000
CY2021Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
35485000
CY2020Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
4919000
CY2021Q3 adgi Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
39900000
CY2021Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2021Q3 adgi Amount Paid For Services
AmountPaidForServices
500000
adgi Amount Paid For Services
AmountPaidForServices
900000
CY2020Q3 adgi Amount Paid For Services
AmountPaidForServices
300000
adgi Amount Paid For Services
AmountPaidForServices
300000
adgi Quarterly Fee
QuarterlyFee
1300000
CY2021Q3 adgi Quarterly Fee
QuarterlyFee
1300000
adgi Quarterly Fee
QuarterlyFee
1300000
adgi Delivery Fee
DeliveryFee
200000
adgi Completion Fee
CompletionFee
200000
adgi Exercise Fee
ExerciseFee
1000000.0
CY2021Q3 adgi Accrued Upfront Fee
AccruedUpfrontFee
200000
us-gaap Royalty Expense
RoyaltyExpense
0
CY2020Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
169548000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
169900000
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
63239670
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
36417895
CY2021Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
five-for-one
adgi Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
200000
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q3 adgi Lessee Operating Lease Total Lease Space
LesseeOperatingLeaseTotalLeaseSpace
9600
CY2021Q3 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
400000
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
150000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
16944484
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.51
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.21
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
12647934
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
12647934
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
12647934
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2968070
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.78
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y9M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11362000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14725078
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
232187
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.68
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17460961
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
586814000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
17460961
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y6M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
586814000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1025630
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
40943000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
6943240
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
adgi Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod
1350000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
5593240
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1734101
adgi Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3859139
adgi Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-48106000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61297086
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5979000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9908000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
86700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y7M6D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
66098810
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1847826
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20346771
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6375000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 adgi Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-60375000
CY2020Q3 adgi Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-48008000
adgi Net Income Loss Available To Common Stockholders
NetIncomeLossAvailableToCommonStockholders
-143748000
CY2021Q3 adgi Net Income Loss Per Share Attributable To Common Stockholders Basic And Diluted
NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted
-0.98
CY2020Q3 adgi Net Income Loss Per Share Attributable To Common Stockholders Basic And Diluted
NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted
-25.98
adgi Net Income Loss Per Share Attributable To Common Stockholders Basic And Diluted
NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted
-7.06
adgi Net Income Loss Per Share Attributable To Common Stockholders Basic And Diluted
NetIncomeLossPerShareAttributableToCommonStockholdersBasicAndDiluted
-7.55
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21320100
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21320100

Files In Submission

Name View Source Status
0000950170-21-004586-index-headers.html Edgar Link pending
0000950170-21-004586-index.html Edgar Link pending
0000950170-21-004586.txt Edgar Link pending
0000950170-21-004586-xbrl.zip Edgar Link pending
adgi-20210930.htm Edgar Link pending
adgi-20210930.xsd Edgar Link pending
adgi-20210930_cal.xml Edgar Link unprocessable
adgi-20210930_def.xml Edgar Link unprocessable
adgi-20210930_htm.xml Edgar Link completed
adgi-20210930_lab.xml Edgar Link unprocessable
adgi-20210930_pre.xml Edgar Link unprocessable
adgi-ex10_1.htm Edgar Link pending
adgi-ex10_2.htm Edgar Link pending
adgi-ex31_1.htm Edgar Link pending
adgi-ex31_2.htm Edgar Link pending
adgi-ex32_1.htm Edgar Link pending
adgi-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending